Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Jazz Pharmaceuticals (JAZZ) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Jazz Pharmaceuticals (JAZZ) lobbying for?
Summary of Jazz Pharmaceuticals lobbying data:
– Lobbying firms hired: Olsson, Frank, Avenue Solutions, Tarplin, Terman & Matz, Weeda, Pc, Llc, Downs & Young, Tiber Creek Group
– General issues they lobbied on: Copyright/Patent/Trademark, Medical/Disease Research/Clinical Labs, Budget/Appropriations, Health Issues
– Specific issues they lobbied on: Healthcare policy and appropriations issues, Consolidated Appropriations Act, Appropriations issues related to House Ag/FDA Appropriations bill pertaining to FDA enforcement of non-FDA approved, and orphan drugs; H.R. 5585, Food and Drug Amendments of 2022 drug safety, drug pricing, Appropriations issues, including accelerated approval, Farm Bill, Food and Drug Amendments of 2022 H.R. 2617, Issues related to cannabis research; S. 253 Cannabidiol and Marihuana Research Expansion Act; issues related to the FDA; issues related to Cannabis research at Health and Human Services., Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), H.R. 6833, Issues related to the FDA and S. 3032 – the FDA STATES Act (115th Congress), Affordable Prescriptions for Patients Act of 2021, 2023 drug safety, cannabis derived CBD products., 2022 (PL 117-103), FDA, The Advanced Research Project Agency-Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; Consolidated Appropriations Act, Build Back Better Act; Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, 2023 (PL 117-328)., expanding home and community based services, the Inflation Reduction Act S. 4348, Appropriations issues related to the House Ag/ FDA Appropriations bill pertaining to FDA enforcement of non-FDA approved, Issues related to cannabis research; S.253 – Cannabidiol and Marihuana Research Expansion Act; issues related to the FDA; issues related to Cannabis research at Health and Human Services., reimportation, prescription drug reform; Issues related to FDA user fee reauthorization bills ( H.R. 7667, FDA and DEA issues, Drug safety issues; Monitor drug pricing legislation; Issues related to FDA user fee reauthorization bills ( H.R. 7667,
– Government agencies they lobbied: White House Office, House of Representatives, Food & Drug Administration (FDA), Department of Health & Human Services (HHS), Senate
One could infer that Jazz Pharmaceuticals is lobbying on a range of healthcare-related issues in order to influence policy decisions that could impact their business operations and profitability. Specifically, the company may be seeking to shape legislation related to the FDA’s oversight of non-FDA approved drugs and orphan drugs, which could have a direct impact on Jazz Pharmaceuticals’ product portfolio. In addition, lobbying on drug pricing, prescription drug reform, and user fee reauthorization bills suggests that the company is trying to position itself favorably in a policy environment where drug prices and access to medication are major concerns. Finally, the company’s lobbying on cannabis research and related issues may be an attempt to influence regulations around the use of medical marijuana, which could create new business opportunities for Jazz Pharmaceuticals.
